What was the outcome of the CATT study regarding the comparison of Ranibizumab and Bevacizumab?

The outcome of the CATT study indicated no significant differences in visual acuity outcomes between Ranibizumab and Bevacizumab when used for the treatment of neovascular age-related macular degeneration (AMD). This large randomized trial aimed to assess the effectiveness and safety of both medications, which are both anti-VEGF therapies but are different in formulation and regulatory approval.

This equality in outcomes suggests that both treatments are comparable in terms of their ability to improve or stabilize vision for patients suffering from AMD. The study played a crucial role in guiding clinical decisions about which therapy to choose, emphasizing that the choice might depend on other factors, including cost or patient-specific considerations, rather than efficacy alone. The analysis confirmed that both agents are viable options for treating this condition, leading to shifts in practice patterns among clinicians.